ESMO Breast 2022 | PerELISA: overexpression of 13 genes associated with endocrine sensitivity in HR+/HER2+ BC

Gaia Griguolo, MD, University of Padova, Padova, Italy, discusses the characterization of genomic features associated with endocrine sensitivity in a the translational of the Phase II PerELISA (NCT02411344) trial. The Phase II trial assessed the activity of de-escalated neoadjuvant pertuzumab plus trastuzumab in combination with letrozole without chemotherapy in patients with HR-positive/HER2-positive (HR+/HER2+) breast cancer. In the translational analysis, the expression of 555 genes was evaluates at baseline from 56 patients. 13 genes were identified to be overexpressed in endocrine-sensitive breast cancer, compared to non-endocrine sensitive. RB loss signature was also evaluated, and found to be associated with higher pathologic complete response (pCr) rates in triple-positive breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.